ALK and lung adenocarcinoma: We describe the case of a 63-year-old man with a stage cIVA <i>ALK</i>-rearranged lung adenocarcinoma who developed a <i>BRAF</i> A598-T599insV mutation as a potential resistance mechanism to alectinib, a second-generation ALK TKI.